Retatrutide vs semaglutide vs tirzepatide

The difference in one sentence

Semaglutide targets one receptor, tirzepatide two and retatrutide three. That structural distinction is where every other difference originates.

Receptor targets

All three are peptides derived from or modelled on endogenous incretin hormones. They differ in which receptors they bind:

Regulatory status differs materially

Semaglutide and tirzepatide hold marketing authorisation in the European Union and are prescribed there as medicines. Retatrutide does not: it is in clinical development and is not authorised as a medicine anywhere.

That difference is not a detail. It determines which regime a substance falls under, what documentation accompanies it and in what context it may be used. We supply retatrutide strictly for laboratory research.

What this article deliberately does not cover

We make no statements about efficacy, weight loss, side effects, dosing or which compound is superior. Those questions belong with the primary literature and, where authorised medicines are concerned, with a physician or pharmacist.

Primary sources

For published research and ongoing studies, the registries themselves are the most reliable entry point:

• ClinicalTrials.gov
• PubMed
• PubChem
• EMA